One site for Breaking News, Politics, Sports, Entertainment & more!

Newz Chooze
Back

Biogen Inc. shares declined in the extended session Wednesday after the U.S. Patent and Trademark Office said Mylan NV could likely succeed in a patent challenge to a Biogen multiple sclerosis drug. Biogen shares fell 2.8% after hours, following a 1.1% decline to close at $333.24. In a decision, the USPTO said that of 20 patent claims against Biogen's drug Tecfidera, Mylan "has demonstrated a reasonable likelihood that it will succeed on at least one of its challenges to patentability." On the other hand, shares of Mylan also declined, falling 1.5% after hours, following a 0.4% decline to close at $30.97. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.